ArticleBMC pulmonary medicine2025
Prevalence and prognostic value of elevated urinary albumin excretion in patients with asthma: analysis of NHANES 2001-2018.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated urinary albumin excretion, quantified as the urinary albumin-to-creatinine ratio (UACR), is a marker of endothelial injury and chronic kidney disease. This study investigates the prevalence and prognostic significance of elevated UACR in asthma patients.
methodsUsing data from the National Health and Nutrition Examination Survey (NHANES 2001-2018), 6,930 adults with asthma were analyzed. Participants were stratified by UACR categories: < 30 mg/g (Group 1), 30-300 mg/g (Group 2), and ≥ 300 mg/g (Group 3). Furthermore, for Group1, we further divided it into tertiles. Kaplan-Meier curves, Cox proportional hazards models, restricted cubic splines, and subgroup analyses were employed to assess associations between UACR and mortality.
resultsAmong 6,930 adults with asthma, 809 all-cause and 195 cardiovascular deaths occurred. Elevated UACR was prevalent in 12.6% (Group 2: 10.5%, Group 3: 2.1%). Compared to Group 1, Group 3 had a higher risk of all-cause mortality (HR: 2.60, 95% CI:1.44-4.71) and cardiovascular mortality (HR: 2.50, 95% CI:1.13-5.55) after full adjustment. Even within the normal range (UACR < 30 mg/g), the highest tertile (Tertile 3) exhibited increased all-cause mortality (HR: 1.69, 95% CI:1.10-2.59). Restricted cubic splines revealed a linear dose-response relationship between UACR and mortality (P for nonlinearity > 0.05). Subgroup analyses confirmed consistency across age, sex, BMI, and comorbidity strata.
conclusionsElevated UACR is independently associated with higher all-cause mortality in adults with asthma, even at levels below the traditional threshold for albuminuria. These findings underscore UACR as a prognostic biomarker for risk stratification in asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.